Äèñêóññèîííûé Êëóá

Âåðíóòüñÿ   Äèñêóññèîííûé Êëóá > Ôîðóìû âðà÷åáíûõ êîíñóëüòàöèé > Íåâðîëîãèÿ è íåéðîõèðóðãèÿ > Ôîðóì äëÿ îáùåíèÿ âðà÷åé íåâðîëîãîâ è íåéðîõèðóðãîâ

Ôîðóì äëÿ îáùåíèÿ âðà÷åé íåâðîëîãîâ è íåéðîõèðóðãîâ Ôîðóì ïðåäíàçíà÷åí äëÿ îáùåíèÿ âðà÷åé ìåæäó ñîáîé.

Îòâåò
 
Îïöèè òåìû Ïîèñê â ýòîé òåìå Îïöèè ïðîñìîòðà
  #136  
Ñòàðûé 27.10.2011, 23:53
Jaina Jaina âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 22.10.2011
Ãîðîä: Ñàíêò- Ïåòåðáóðã
Ñîîáùåíèé: 11
Ñêàçàë(à) ñïàñèáî: 5
Ïîáëàãîäàðèëè 1 ðàç çà 1 ñîîáùåíèå
Jaina *
Ñïàñèáî çà ññûëêó.
Îòâåòèòü ñ öèòèðîâàíèåì
  #137  
Ñòàðûé 04.03.2012, 13:06
limarodessa limarodessa âíå ôîðóìà
Ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 27.09.2009
Ãîðîä: Îäåññà
Ñîîáùåíèé: 129
Ñêàçàë(à) ñïàñèáî: 21
Ïîáëàãîäàðèëè 17 ðàç(à) çà 16 ñîîáùåíèé
limarodessa ýòîò ó÷àñòíèê èìååò ïëîõóþ ðåïóòàöèþ íà ôîðóìå
Ýòî áåçóñëîâíî íå èíñóëüò è íå ×ÌÒ. Íî ñàì ôàêò òîãî ÷òî î òâîðåíèè ôèðìû UCB ñåðåäèíû 60-õ ãîäîâ è òåïåðü íå çàáûëè ëþáîïûòåí - 2012 ãîä è åâðîïåéñêèé æóðíàë. Ïðàâèëà EBM âðîäå áû ñîáëþäåíû. Õîòÿ íå âèæó ìóëüòèöåíòðèðóþùåé è ðàíäîìèçèðóþùåé êîìïîíåíò

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Öèòàòà:
Double-blind, placebo-controlled trial on the effect of piracetam on breath-holding spells

Breath-holding spells (BHS) are apparently frightening events occurring in otherwise healthy children. The aim of this study was to evaluate the efficacy of piracetam in the treatment of breath-holding spells. Forty patients with BHS (who were classified into two groups) were involved in a double-blinded placebo-controlled prospective study. Piracetam was given to group A while group B received placebo. Patients were followed monthly for a total period of 4 months. The numbers of attacks/month before and monthly after treatment were documented, and the overall number of attacks/month after treatment was calculated in both groups. The median number of attacks/month before treatment in the two groups was 5.5 and 5, respectively, while after the first month of treatment, it was 2 and 5, respectively. The median overall number of attacks/month after treatment in both groups was 1 and 5, respectively. There was a significant decline of number of attacks after piracetam treatment compared to placebo (p value < 0.001). There were no reported side effects of the piracetam throughout the study period. In conclusion, piracetam is a safe and effective drug for the treatment of breath-holding spells in children.
Îòâåòèòü ñ öèòèðîâàíèåì
  #138  
Ñòàðûé 04.03.2012, 13:23
limarodessa limarodessa âíå ôîðóìà
Ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 27.09.2009
Ãîðîä: Îäåññà
Ñîîáùåíèé: 129
Ñêàçàë(à) ñïàñèáî: 21
Ïîáëàãîäàðèëè 17 ðàç(à) çà 16 ñîîáùåíèé
limarodessa ýòîò ó÷àñòíèê èìååò ïëîõóþ ðåïóòàöèþ íà ôîðóìå
À âîò åùå (íå çíàþ ïîäïàäàþò ëè 24 íåäåëè ïîä êàòåãîðèþ êîíå÷íûõ òî÷åê):

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Öèòàòà:
Journal of Stroke and Cerebrovascular Diseases

Volume 20, Issue 4, July–August 2011, Pages 310–318

Cerebrolysin in Vascular Dementia: Improvement of Clinical Outcome in a Randomized, Double-Blind, Placebo-Controlled Multicenter Trial

No drug to treat vascular dementia (VaD) has yet been approved by the American or European authorities, leaving a large population of patients without effective therapy. Cerebrolysin has a long record of safety and might be efficacious in this condition. We conducted a large, multicenter, double-blind, placebo-controlled study in 242 patients meeting the criteria for VaD. The primary endpoint was the combined outcome of cognition (based on Alzheimer's Disease Assessment Scale Cognitive Subpart, Extended Version [ADAS-cog+] score) and overall clinical functioning (based on Clinician's Interview-Based Impression of Change plus Caregiver Input [CIBIC+] score) assessed after 24 weeks of treatment. Intravenous Cerebrolysin 20 mL was administered once daily over the course of 2 treatment cycles as add-on therapy to basic treatment with acetylsalicylic acid. The addition of Cerebrolysin was associated with significant improvement in both primary parameters. At week 24, ADAS-cog+ score improved by 10.6 points in the Cerebrolysin group, compared with 4.4 points in the placebo group (least squares mean difference, −6.17; P < .0001 vs placebo). CIBIC+ showed a mean improvement of 2.84 in the treatment arm and 3.68 in the placebo arm, a treatment difference of 0.84 (P < .0001 vs placebo). These findings were confirmed by responder analyses demonstrating higher rates in the Cerebrolysin group (ADAS-cog+ improvement of ≥4 points from baseline, 82.1% vs 52.2%; CIBIC+ score of <4 at week 24, 75.3% vs 37.4%; combined response in ADAS-cog+ and CIBIC+, 67.5% vs 27.0%). For Cerebrolysin, the odds ratio for achieving a favorable CIBIC+ response was 5.08 (P < .05), and that for achieving a favorable combined response was 5.63 (P < .05). Our data indicate that the addition of Cerebrolysin significantly improved clinical outcome, and that the benefits persisted for at least 24 weeks. Cerebrolysin was safe and well tolerated
Îòâåòèòü ñ öèòèðîâàíèåì
  #139  
Ñòàðûé 04.03.2012, 16:49
limarodessa limarodessa âíå ôîðóìà
Ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 27.09.2009
Ãîðîä: Îäåññà
Ñîîáùåíèé: 129
Ñêàçàë(à) ñïàñèáî: 21
Ïîáëàãîäàðèëè 17 ðàç(à) çà 16 ñîîáùåíèé
limarodessa ýòîò ó÷àñòíèê èìååò ïëîõóþ ðåïóòàöèþ íà ôîðóìå
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Öèòàòà:

Homocysteine-Lowering by B Vitamins Slows the Rate of Accelerated Brain Atrophy in Mild Cognitive Impairment: A Randomized Controlled Trial

An increased rate of brain atrophy is often observed in older subjects, in particular those who suffer from cognitive decline. Homocysteine is a risk factor for brain atrophy, cognitive impairment and dementia. Plasma concentrations of homocysteine can be lowered by dietary administration of B vitamins.
Objective

To determine whether supplementation with B vitamins that lower levels of plasma total homocysteine can slow the rate of brain atrophy in subjects with mild cognitive impairment in a randomised controlled trial (VITACOG, ISRCTN 94410159).
Methods and Findings

Single-center, randomized, double-blind controlled trial of high-dose folic acid, vitamins B6 and B12 in 271 individuals (of 646 screened) over 70 y old with mild cognitive impairment. A subset (187) volunteered to have cranial MRI scans at the start and finish of the study. Participants were randomly assigned to two groups of equal size, one treated with folic acid (0.8 mg/d), vitamin B12 (0.5 mg/d) and vitamin B6 (20 mg/d), the other with placebo; treatment was for 24 months. The main outcome measure was the change in the rate of atrophy of the whole brain assessed by serial volumetric MRI scans.
Results

A total of 168 participants (85 in active treatment group; 83 receiving placebo) completed the MRI section of the trial. The mean rate of brain atrophy per year was 0.76% [95% CI, 0.63–0.90] in the active treatment group and 1.08% [0.94–1.22] in the placebo group (P = 0.001). The treatment response was related to baseline homocysteine levels: the rate of atrophy in participants with homocysteine >13 µmol/L was 53% lower in the active treatment group (P = 0.001). A greater rate of atrophy was associated with a lower final cognitive test scores. There was no difference in serious adverse events according to treatment category.
Conclusions and Significance

The accelerated rate of brain atrophy in elderly with mild cognitive impairment can be slowed by treatment with homocysteine-lowering B vitamins. Sixteen percent of those over 70 y old have mild cognitive impairment and half of these develop Alzheimer's disease. Since accelerated brain atrophy is a characteristic of subjects with mild cognitive impairment who convert to Alzheimer's disease, trials are needed to see if the same treatment will delay the development of Alzheimer's disease.
Îòâåòèòü ñ öèòèðîâàíèåì
  #140  
Ñòàðûé 04.03.2012, 16:54
limarodessa limarodessa âíå ôîðóìà
Ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 27.09.2009
Ãîðîä: Îäåññà
Ñîîáùåíèé: 129
Ñêàçàë(à) ñïàñèáî: 21
Ïîáëàãîäàðèëè 17 ðàç(à) çà 16 ñîîáùåíèé
limarodessa ýòîò ó÷àñòíèê èìååò ïëîõóþ ðåïóòàöèþ íà ôîðóìå
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Öèòàòà:
Objective: To investigate whether supplementing older men with vitamins B12, B6, and folic acid improves cognitive function.

Methods: The investigators recruited 299 community-representative hypertensive men 75 years and older to a randomized, double-blind controlled clinical trial of folic acid, vitamin B6, and B12 supplementation vs placebo over 2 years. The primary outcome of interest was the change in the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog). A secondary aim of the study was to determine if supplementation with vitamins decreased the risk of cognitive impairment and dementia over 8 years.

Results: The groups were well-balanced for demographic and biochemical parameters. There was no difference in the ADAS-cog change from baseline to 24 months between the placebo (0.8, SD 4.0) and vitamins group (0.7, SD 3.4). The adjusted scores in the treatment groups did not differ over time (placebo 0.2 lower, z = 0.71, p = 0.478). There was a nonsignificant 28% decrease in the risk of cognitive impairment (odds ratio 0.72, 95% confidence interval 0.25–2.09) and dementia (hazard ratio 0.72, 95% confidence interval 0.29–1.78) over 8 years of follow-up.

Conclusions: The daily supplementation of vitamins B12, B6, and folic acid does not benefit cognitive function in older men, nor does it reduce the risk of cognitive impairment or dementia.

Classification of evidence: This study provides Class I evidence that vitamin supplementation with daily doses of 400 μg of B12, 2 mg of folic acid, and 25 mg of B6 over 2 years does not improve cognitive function in hypertensive men aged 75 and older.
Îòâåòèòü ñ öèòèðîâàíèåì
  #141  
Ñòàðûé 04.03.2012, 17:03
limarodessa limarodessa âíå ôîðóìà
Ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 27.09.2009
Ãîðîä: Îäåññà
Ñîîáùåíèé: 129
Ñêàçàë(à) ñïàñèáî: 21
Ïîáëàãîäàðèëè 17 ðàç(à) çà 16 ñîîáùåíèé
limarodessa ýòîò ó÷àñòíèê èìååò ïëîõóþ ðåïóòàöèþ íà ôîðóìå
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Öèòàòà:
Purpose

We aimed to quantify the effect of folic acid supplementation on the prevention of cognitive decline.
Methods

We conducted a meta-analysis of 9 placebo-controlled randomized trials (2835 participants, median duration 6 months) of folic acid, with or without other B vitamins, on cognitive function. Standardized mean differences in cognitive function test scores were calculated between folic acid and placebo-treated groups.
Results

The standardized mean difference in cognitive function test scores was 0.01 (95% confidence interval [95% CI], −0.08 to 0.10), or an increase of 1% (95% CI, −8% to 10%) of 1 standard deviation. The results were similar within each of the 4 categories of cognitive function (memory, speed, language, and executive function); standardized mean differences were 0.01 (95% CI, −0.08 to 0.09), −0.01 (95% CI, −0.10 to 0.13), −0.05 (95% CI, −0.15 to 0.04), and 0.03 (95% CI, −0.13 to 0.19), respectively.
Conclusion

Randomized trials show no effect of folic acid, with or without other B vitamins, on cognitive function within 3 years of the start of treatment. Trials of longer duration, recording the incidence of dementia, as well as cognitive decline, are needed.
Îòâåòèòü ñ öèòèðîâàíèåì
  #142  
Ñòàðûé 04.03.2012, 17:16
limarodessa limarodessa âíå ôîðóìà
Ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 27.09.2009
Ãîðîä: Îäåññà
Ñîîáùåíèé: 129
Ñêàçàë(à) ñïàñèáî: 21
Ïîáëàãîäàðèëè 17 ðàç(à) çà 16 ñîîáùåíèé
limarodessa ýòîò ó÷àñòíèê èìååò ïëîõóþ ðåïóòàöèþ íà ôîðóìå
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Öèòàòà:
Background

Homocysteine is a risk factor for Alzheimer's disease. In the first report on the VITACOG trial, we showed that homocysteine-lowering treatment with B vitamins slows the rate of brain atrophy in mild cognitive impairment (MCI). Here we report the effect of B vitamins on cognitive and clinical decline (secondary outcomes) in the same study.
Methods

This was a double-blind, single-centre study, which included participants with MCI, aged ≥70 y, randomly assigned to receive a daily dose of 0.8 mg folic acid, 0.5 mg vitamin B12 and 20 mg vitamin B6 (133 participants) or placebo (133 participants) for 2 y. Changes in cognitive or clinical function were analysed by generalized linear models or mixed-effects models.
Results

The mean plasma total homocysteine was 30% lower in those treated with B vitamins relative to placebo. B vitamins stabilized executive function (CLOX) relative to placebo (P = 0.015). There was significant benefit of B-vitamin treatment among participants with baseline homocysteine above the median (11.3 µmol/L) in global cognition (Mini Mental State Examination, P < 0.001), episodic memory (Hopkins Verbal Learning Test–delayed recall, P = 0.001) and semantic memory (category fluency, P = 0.037). Clinical benefit occurred in the B-vitamin group for those in the upper quartile of homocysteine at baseline in global clinical dementia rating score (P = 0.02) and IQCODE score (P = 0.01).
Conclusion

In this small intervention trial, B vitamins appear to slow cognitive and clinical decline in people with MCI, in particular in those with elevated homocysteine. Further trials are needed to see if this treatment will slow or prevent conversion from MCI to dementia. Copyright © 2011 John Wiley & Sons, Ltd.
Îòâåòèòü ñ öèòèðîâàíèåì
  #143  
Ñòàðûé 04.03.2012, 19:40
opto_dive opto_dive âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 15.09.2008
Ãîðîä: Ðîññèÿ
Ñîîáùåíèé: 2,573
Ñêàçàë(à) ñïàñèáî: 100
Ïîáëàãîäàðèëè 460 ðàç(à) çà 445 ñîîáùåíèé
Çàïèñåé â äíåâíèêå: 3
opto_dive ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåopto_dive ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåopto_dive ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåopto_dive ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåopto_dive ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåopto_dive ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåopto_dive ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåopto_dive ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåopto_dive ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåopto_dive ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Limarodessa, õâàòèò òàùèòü âñå ïîäðÿä. Ãäå â Âàøèõ ññûëêàõ åñòü "ÈÍÑÓËÜÒ". Ïðèäåò ìîäåðàòîð è êóïèðóåò ýòîò ïðîöåññ.
È ïðî öåðåáðîëèçèí óæå áûëî - http://forums.rusmedserv.com/showpos...&postcount=107 Ê òîìó æå ïîñìîòðèòå êòî â ýòîì èññëåäîâàíèè "ñïîíñèðîâàë" è êòî ïðîèçâîäèòåëü. (ýòî èíôîðìàöèÿ â ñêðûòîì ðåæèìå áûëà îáñóæäåíà íåâðîëîãàìè, íå ïîäóìàéòå, ÷òî ÿ òàêîé óìíûé)
ç.û. äîáàâüòå â âàøè ïîèñêè ñëîâî "stroke", íàìíîãî ìåíüøå ñòàíåò ðåçóëüòàòîâ.
Îòâåòèòü ñ öèòèðîâàíèåì
  #144  
Ñòàðûé 04.03.2012, 19:45
limarodessa limarodessa âíå ôîðóìà
Ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 27.09.2009
Ãîðîä: Îäåññà
Ñîîáùåíèé: 129
Ñêàçàë(à) ñïàñèáî: 21
Ïîáëàãîäàðèëè 17 ðàç(à) çà 16 ñîîáùåíèé
limarodessa ýòîò ó÷àñòíèê èìååò ïëîõóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò opto_dive Ïîñìîòðåòü ñîîáùåíèå
Limarodessa, õâàòèò òàùèòü âñå ïîäðÿä. Ãäå â Âàøèõ ññûëêàõ åñòü "ÈÍÑÓËÜÒ". Ïðèäåò ìîäåðàòîð è êóïèðóåò ýòîò ïðîöåññ.
ç.û. äîáàâüòå â âàøè ïîèñêè ñëîâî "stroke", íàìíîãî ìåíüøå ñòàíåò ðåçóëüòàòîâ.
Äà äåéñòâèòåëüíî. Ýòî òàê. Åñëè áû áûëà áîëåå ðåëåâàíòíàÿ òåìà òî ýòî ñëåäîâàëî áû ðàçìåñòèòü íå çäåñü.

Ñòðîóê è ×ÌÒ ýòî óðãåíòíûå, êàòàñòðîôè÷åñêèå ñèòóàöèè. Äëÿ íèõ íîîòðîïû ÿâíî íåýôôåêòèâíû. Çäåñü áåç ïåðñïåêòèâíûõ ìåòîäîâ ðåàíèìàòîëîãèè, íåéðîõèðóðãèè è ïîñëåäóþùåé íåéðîòðàíñïëàíòàöèè ýôôåêòà íåðåàëüíî äîñòè÷ü. À äëÿ ïåðìàíåíòíûõ äèôôóçíûõ ïðîöåññîâ îáóñëîâëåííûõ öåðåáðîâàñêóëÿðíûìè äåôèöèòàìè ïî âèäèìîìó îò íåéðîòðîôè÷åñêèõ ôàêòîðîâ íå ñëåäóåò ïîëíîñòüþ îòêàçûâàòüñÿ.

Êîììåíòàðèè ê ñîîáùåíèþ:
opto_dive îäîáðèë(à): â ÷åì ïðîáëåìà, ñîçäàéòå.  ïåðâûé ðàç "îäîáðÿþ", òîëüêî íå ôëóäèòå.
Îòâåòèòü ñ öèòèðîâàíèåì
  #145  
Ñòàðûé 04.03.2012, 19:57
limarodessa limarodessa âíå ôîðóìà
Ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 27.09.2009
Ãîðîä: Îäåññà
Ñîîáùåíèé: 129
Ñêàçàë(à) ñïàñèáî: 21
Ïîáëàãîäàðèëè 17 ðàç(à) çà 16 ñîîáùåíèé
limarodessa ýòîò ó÷àñòíèê èìååò ïëîõóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò opto_dive Ïîñìîòðåòü ñîîáùåíèå
... ïîñìîòðèòå êòî â ýòîì èññëåäîâàíèè "ñïîíñèðîâàë" è êòî ïðîèçâîäèòåëü. (ýòî èíôîðìàöèÿ â ñêðûòîì ðåæèìå áûëà îáñóæäåíà íåâðîëîãàìè, íå ïîäóìàéòå, ÷òî ÿ òàêîé óìíûé)... ðåçóëüòàòîâ.
Äà ÿ äîãàäàëñÿ åù¸ äî òîãî êàê Âû íàïèñàëè (íå ïîäóìàéòå ÷òî ÿ ñîâñåì óæ òàêîé ÍÅ óìíûé) ÷òî "íåçàâèñèìîñòü" àâòîðîâ ñòàòåé îáñóæäàëè çäåñü íà ôîðóìå â çàêðûòûõ îò îáû÷íûõ ïîñåòèòåëåé òåìàõ Îò ñåáÿ äîáàâëþ ÷òî íóæíî òàêæå îáñóæäàòü ðåöåíçåíòîâ ñòàòåé (áåç íèõ ñòàòüÿ íå ìîæåò áûòü ïðèíÿòà â æóðíàë - óæ ÿ òî çíàþ), è ðåäêîëëåãèè æóðíàëîâ. Ñåðüåçíûå æóðíàëû ýòî íå ñòîëü ïðîñòûå ñòðóêòóðû.  íèõ î÷åíü áîëüøîé îòñåâ ñòàòåé, è ïîâëèÿòü íà íèõ íå òàê ïðîñòî åñëè âîîáùå âîçìîæíî. Îïóáëèêîâàòüñÿ â ïðèçíàííîì çàïàäíîì íàó÷íîì æóðíàëå âåñüìà è âåñüìà ïðîáëåìàòè÷íî.
Îòâåòèòü ñ öèòèðîâàíèåì
  #146  
Ñòàðûé 04.03.2012, 22:01
limarodessa limarodessa âíå ôîðóìà
Ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 27.09.2009
Ãîðîä: Îäåññà
Ñîîáùåíèé: 129
Ñêàçàë(à) ñïàñèáî: 21
Ïîáëàãîäàðèëè 17 ðàç(à) çà 16 ñîîáùåíèé
limarodessa ýòîò ó÷àñòíèê èìååò ïëîõóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò opto_dive Ïîñìîòðåòü ñîîáùåíèå
... ïîñìîòðèòå êòî â ýòîì èññëåäîâàíèè "ñïîíñèðîâàë" è êòî ïðîèçâîäèòåëü...
Íàñòîÿùàÿ ïîëíîöåííàÿ ïðîöåäóðà ðåöåíçèðîâàíèÿ - ïðîöåäóðà äîïóñêà ñòàòüè äëÿ ïóáëèêàöèè â æóðíàëå ïóòåì ïðîâåðêè íåçàâèñèìûì ýêñïåðòîì îñóùåñòâëÿåòñÿ àíîíèìíî. Òî åñòü íè àâòîð ñòàòüè íè ðåöåíçåíò íå äîëæíû è íå èìåþò âîçìîæíîñòè çíàòü äðóã äðóãà â äàííîé ñèòóàöèè (õîòÿ â æèçíè ìîãóò ðàáîòàòü â ñîñåäíèõ êàáèíåòàõ è âèäåòüñÿ êàæäûé äåíü):

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Öèòàòà:
...A brief autobiographical note containing relevant details about the author should be included on a separate page. In order to maintain the anonymity of the peer review process, authors should ensure that their own name does not appear anywhere in their submission. References to authors' own work should be anonymised as far as possible to prevent the author from being identifiable....
Òàêèì îáðàçîì äîëæíà ìèíèìèçèðîâàòüñÿ âåðîÿòíîñòü êîððóïöèè è/èëè îêàçàíèÿ äàâëåíèÿ íà ðåöåíçåíòà. Òàê ÷òî ýêñïåðò íå òî ÷òîáû "ñïîíñîðîâ" çíàòü â èäåàëå íå ìîæåò íî è äàæå ýêñïåðèìåíòàòîðà. À ïðèìåò æóðíàë ñòàòüþ èëè íåò çàâèñèò èìåííî îò ýêñïåðòà îñóùåñòâëÿþùåãî ðåöåíçèðîâàíèå. Ê òîìó æå êàê ïðàâèëî àâòîðû â ñòàòüÿõ ïóáëèêóþò íå ïåðâóþ è íå äåñÿòóþ ñâîþ ñòàòüþ. È åñëè àâòîð áóäåò ïîéìàí íàó÷íûì ñîîáùåñòâîì íà ïîïûòêàõ ëîááèðîâàíèÿ èíòåðåñîâ ôàðìèíäóñòðèè òî òàêîìó "èññëåäîâàòåëþ" äîðîãà â íàó÷íóþ ïåðèîäèêó áóäåò çàêðûòà íàâñåãäà. Ïðåñòèæíûå æóðíàëû ñâîþ ðåïóòàöèþ ïîä óäàð íå ñòàâÿò. Êîíå÷íî íå âñå òàê èäåàëüíî îáñòîèò íà ïðàêòèêå. Íå ñëåäóåò áûòü ñòîëü äåìàãîãè÷åñêè-íàèâíûìè. Íî âñå æå...
Îòâåòèòü ñ öèòèðîâàíèåì
  #147  
Ñòàðûé 15.04.2012, 18:42
efns efns âíå ôîðóìà ÂÐÀ×
çàáàíåí
 
Ðåãèñòðàöèÿ: 16.01.2006
Ãîðîä: Íîâîñèáèðñê
Ñîîáùåíèé: 284
Ñêàçàë(à) ñïàñèáî: 23
Ïîáëàãîäàðèëè 16 ðàç(à) çà 16 ñîîáùåíèé
efns ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåefns ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Âîïðîñ

Èçâèíèòå, êîëëåãè, îáñóæäåíèå ñâÿçàíî ñ ÷åì-òî îñîáåííûì èëè îïÿòü öåðåáðîëèçèí ââåëè â æâíëñ.?

Êîììåíòàðèè ê ñîîáùåíèþ:
Iluhin íå îäîáðèë(à): Íà äàòó ïåðâîãî ïîñòà ïîñìîòðèòå
Îòâåòèòü ñ öèòèðîâàíèåì
  #148  
Ñòàðûé 17.04.2012, 14:22
efns efns âíå ôîðóìà ÂÐÀ×
çàáàíåí
 
Ðåãèñòðàöèÿ: 16.01.2006
Ãîðîä: Íîâîñèáèðñê
Ñîîáùåíèé: 284
Ñêàçàë(à) ñïàñèáî: 23
Ïîáëàãîäàðèëè 16 ðàç(à) çà 16 ñîîáùåíèé
efns ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåefns ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Äàòà ïîñòà

Ïîñìîòðåë, íî åùå è ãëÿíóë Æíâëñ - âîò òå íó, öåðåáðîëèçèí îïÿòü â ñïèñêàõ ìåäèêàìåíòîâ íåîáõîäèìûõ íàðîäó íà áåñïëàòíîé îñíîâå. Â îáùåì ïèøèòå, ïèøèòå ... Óäèâèòåëüíî! Èëè íåóäèâèòåëüíî!?
Îòâåòèòü ñ öèòèðîâàíèåì
  #149  
Ñòàðûé 05.05.2012, 20:19
tambofff tambofff âíå ôîðóìà ÂÐÀ×
Ïîñòîÿííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 25.11.2010
Ãîðîä: Òàìáîâ
Ñîîáùåíèé: 228
Ñêàçàë(à) ñïàñèáî: 19
Ïîáëàãîäàðèëè 15 ðàç(à) çà 13 ñîîáùåíèé
tambofff ýòîò ó÷àñòíèê èìååò õîðîøóþ ðåïóòàöèþ íà ôîðóìå
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Îòâåòèòü ñ öèòèðîâàíèåì
  #150  
Ñòàðûé 05.05.2012, 20:43
Àâàòàð äëÿ alexdr
alexdr alexdr âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 25.11.2005
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 3,187
Ïîáëàãîäàðèëè 306 ðàç(à) çà 297 ñîîáùåíèé
alexdr ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåalexdr ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåalexdr ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåalexdr ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåalexdr ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåalexdr ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåalexdr ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåalexdr ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåalexdr ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåalexdr ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåalexdr ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
- Ïðèáîðû?
- Ñåìüäåñÿò ïÿòü!
- ×òî ñåìüäåñÿò ïÿòü?
- À ÷òî ïðèáîðû?
Öèòàòà:
Ñîîáùåíèå îò tambofff Ïîñìîòðåòü ñîîáùåíèå
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Ìåíÿ èñêðåííå èçóìëÿåò æåëàíèå íåêîòîðûõ êîëëåã ïóëüíóòü â äèñêóññèè ññûëêàìè. Äåñêàòü, âû òàì ðàçáèðàéòåñü, ÷òî æå ÿ õîòåë ýòèì ñêàçàòü, à ÿ ïîêà ïîêóðþ â ñòîðîíêå. À æèçíü ïîòèõîíüêó òå÷åò è íåìàëàÿ åå ÷àñòü òðàòèòüñÿ íà ïðî÷òåíèå òîãî, ÷òî òàì êîëëåãà çàïóëèë. À âäðóã çà íèìè óìíàÿ ìûñëü ñêðûâàåòñÿ, îïðîâåðãàþùåå âñå ðàíåå íàïèñàííîå, îòêðîâåíèå êàêîå?

Êîììåíòàðèè ê ñîîáùåíèþ:
Iluhin îäîáðèë(à):
__________________
ðóêó êú ñåìó ïðèëîæèëú Àëåêñàíäðú
Îòâåòèòü ñ öèòèðîâàíèåì
Îòâåò



Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 14:22.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.